TG Therapeutics Inc

+0.31 (+1.38%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)3.53B
Current PE85.65
Forward PE N/A
2yr Forward PE 38.69
See more stats
Estimates Current Quarter
Revenue$65.89 Million
Adjusted EPS-$0.05
See more estimates
10-Day MA$20.94
50-Day MA$17.75
200-Day MA$14.81
See more pivots

TG Therapeutics Inc Stock, NASDAQ:TGTX

3020 Carrington Mill Boulevard, Suite 475, Morrisville, North Carolina 27560
United States of America
Phone: +1.212.554.4484
Number of Employees: 264


TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.